Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H26Cl2N4 |
| Molecular Weight | 417.375 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(CCC)N1CCN2N=C(C3=NC(C)=CC1=C23)C4=C(Cl)C=C(Cl)C=C4
InChI
InChIKey=AKLMUGFDGONMAA-UHFFFAOYSA-N
InChI=1S/C22H26Cl2N4/c1-4-6-16(7-5-2)27-10-11-28-22-19(27)12-14(3)25-21(22)20(26-28)17-9-8-15(23)13-18(17)24/h8-9,12-13,16H,4-7,10-11H2,1-3H3
| Molecular Formula | C22H26Cl2N4 |
| Molecular Weight | 417.375 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:02:12 GMT 2023
by
admin
on
Sat Dec 16 12:02:12 GMT 2023
|
| Record UNII |
874OEY3JEJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
874OEY3JEJ
Created by
admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
|
PRIMARY | |||
|
268545-87-5
Created by
admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
|
PRIMARY | |||
|
9888194
Created by
admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
|
PRIMARY | |||
|
NBI-34041
Created by
admin on Sat Dec 16 12:02:12 GMT 2023 , Edited by admin on Sat Dec 16 12:02:12 GMT 2023
|
PRIMARY | Description: NBI-34041 is potent and high-affinity CRF1 receptor antagonist. NBI-34041 is safety and efficacy in attenuating elevated stress response. NBI-34041 is effective in reducing endocrine responses to pharmacological and behavioral challenge mediated by CRF(1) receptors. NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress. NBI-34041 demonstrates that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders. (last updated: 3/8/2016). |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Developer: GlaxoSmithKline; Class: Acenaphthene, Antidepressant, Antispasmodic, Anxiolytic, Irritable bowel syndrome therapy; Mechanism of Action: Corticotropin-releasing factor antagonists; Highest Development Phase: Discontinued for Anxiety disorders, Irritable bowel syndrome and Major depressive disorder
|
||
|
ACTIVE MOIETY |
These specific properties and its well-documented safety profile enabled a clinical Phase I study with 24 healthy male subjects receiving NBI-34041 (10, 50, or 100 mg) or placebo for 14 days. Regulation of the hypothalamic-pituitary-adrenocortical (HPA) axis was evaluated by intravenous stimulation with 100 mg of human CRF. Treatment with NBI-34041 did not impair diurnal adrenocorticotropic hormone(ACTH) and cortisol secretion or CRF evoked ACTH and cortisol responses but attenuated the neuroendocrine response to psychosocial stress.
|
